IntelliPharmaCeutics International (IntelliPharmaCeutics International) Buyback Yield % : 0.00 (As of Apr. 28, 2024)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

IntelliPharmaCeutics International's current buyback yield was 0.00%.

IntelliPharmaCeutics International Buyback Yield % Historical Data

The historical data trend for IntelliPharmaCeutics International's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Buyback Yield % Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Buyback Yield %

Get a 7-Day Free Trial

-326.15

-77.28

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Buyback Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of IntelliPharmaCeutics International's Buyback Yield %

For the Biotechnology subindustry, IntelliPharmaCeutics International's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Buyback Yield % falls into.

IntelliPharmaCeutics International Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

IntelliPharmaCeutics International's Buyback Yield for the fiscal year that ended in Nov. 2022 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0)	/	2.3826744
	=	0.00%

IntelliPharmaCeutics International's annualized Buyback Yield for the quarter that ended in Aug. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	2.61101403
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Aug. 2023) data.

IntelliPharmaCeutics International Buyback Yield % Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.